Search results
Showing 1621 to 1635 of 9127 results
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Sotatercept for treating pulmonary arterial hypertension (TA1161)
Evidence-based recommendations on sotatercept (Winrevair) for pulmonary arterial hypertension in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment in adults.
Evidence-based recommendations on serplulimab (Hetronifly) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults.
Show all sections
Seladelpar for previously treated primary biliary cholangitis (TA1171)
Evidence-based recommendations on seladelpar (Livdelzi) for previously treated primary biliary cholangitis in adults.
Show all sections
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
Evidence-based recommendations on pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
NICE is unable to make a recommendation on nintedanib (Ofev) for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1111
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis (TA1175)
Evidence-based recommendations on glycopyrronium bromide cream (Axhidrox) for treating severe primary axillary hyperhidrosis in adults.
Evidence-based recommendation on teplizumab (Tzield) for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes.
Show all sections
Evidence-based recommendations on cemiplimab (Libtayo) for recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.